Possibility of a new form of therapy for multiple myeloma

Open Book Of prostate multiple myeloma, Conceptual Image


With approximately 6500 new cases, multiple myeloma is the third most common haematological disease in Germany. Patients with such advanced stage myeloma have limited or no treatment options left. A recently published Swedish study has now investigated a possible combination therapy as a potential therapeutic option for these same people.

Open Book Of prostate multiple myeloma, Conceptual Image

shutterstock.com / felipe caparros

Multiple myeloma in more detail:

A plasmocytoma, or multiple myeloma, is a specific type of blood cancer in which human plasma cells in the bone marrow divide uncontrollably. The bone marrow results in the production of red and white blood cells, which have different functions. Red blood cells, also known as erythrocytes, are responsible for transporting oxygen and white blood cells, also known as leukocytes, are produced in the bone marrow for immune defence. In this context, so-called T- or B-cells belong to the subgroups of leukocytes. Plasma cells represent the mature stage of these B cells and serve to produce antibodies. Due to the uncontrolled multiplication of these plasma cells, the immune system is weakened and various symptoms can develop. In the initial stage of cancer in the bone marrow, no symptoms are usually apparent. As the disease progresses, multiple myeloma can cause a variety of symptoms, including back pain, anemia, antibody deficiency, kidney damage, or small skin bleeding.

Association of Research-Based Pharmaceutical Companies:

The Association of Research-Based Pharmaceutical Companies expects a quarter of new drugs in 2021 to target different cancers, with two new T-cell therapies possible to treat multiple myeloma, it said. Idecabtagen vicleucel could find approval in multiple myeloma therapy in 2021. One agent already approved for treatment is isatuximab, which is used in combination with pomalidomide and dexamethasone (has an anti-inflammatory effect).

A Phase 2 study published in December 2020 now evaluated the efficacy of combination therapy with the cancer drug melflufen and dexamethasone in multiple myeloma, which is a population with an important unmet medical need.

Phase 2 Study Method:

While previous lines of therapy have introduced new combinations of antimyeloma drugs, patients with relapsed (i.e., recurrent at intervals) and refractory (i.e.multiple myeloma (RRMM for short) often suffer from disease that is refractory to multiple drugs. Therefore, drugs with new mechanisms of action are urgently needed. In combination with dexamethasone, melflufen could potentially address this unmet medical need by providing a novel mechanism of action, clinically meaningful efficacy and safety in patients with the cancer.

The multicenter Phase 2 trial, published in the Journal of Clinical Oncology, enrolled patients at 17 sites from December 2016 to October 2019. Study participants had a prior diagnosis with multiple myeloma, and measurable disease at study entry. Previously, participants had to have received at least two therapies and had to be insensitive to certain antibodies (i.e., anti-CD38 antibodies). These patients received 40mg of melflufen intravenously on the first day of each 28-day cycle and an additional 40mg of dexamethasone by oral administration once weekly. Here, the primary endpoint of the study was the verified overall response rate to the drugs. Secondary endpoints were: Duration of response, patient survival and safety.


Of 157 patients with a mean age of 65 years and five prior therapies, 55 patients (35%) had extramedullary disease (i.e., outside the bone marrow). The overall response rate was 29% among those treated, while the median duration of response was 5.5 months and median survival was 4.2 months and overall survival was 11.6 months with a follow-up of 14 months.

Treatment-related adverse events occurred in 96% of patients:

  • Neutropenia at 79% (i.e. decrease in white blood cell count).
  • Thrombocytopenia with 76% (i.e. lack of platelets in the blood)
  • anaemia with 43

Pneumonia (10%) was the most common non-hematological (i.e. diseases of the blood) event.


According to the study, combination therapy melflufen and dexamethasone demonstrated clinically meaningful efficacy and manageable safety in patients with heavily pretreated RRMM. As this is a phase 2 trial, it remains to be seen whether this novel form of therapy can be confirmed in further studies and significantly help people who are now insensitive to certain drugs due to previous treatments.

Active ingredients:


    Editorial principles

    All information used for the content comes from verified sources (recognised institutions, experts, studies by renowned universities). We attach great importance to the qualification of the authors and the scientific background of the information. Thus, we ensure that our research is based on scientific findings.
    Danilo Glisic

    Danilo Glisic

    As a biology and mathematics student, he is passionate about writing magazine articles on current medical topics. Due to his affinity for facts, figures and data, his focus is on describing relevant clinical trial results.

    The content of this page is an automated and high-quality translation from DeepL. You can find the original content in German here.

    Last Update





    Your personal medicine assistent

    afgis-Qualitätslogo mit Ablauf Jahr/Monat: Mit einem Klick auf das Logo öffnet sich ein neues Bildschirmfenster mit Informationen über medikamio GmbH & Co KG und sein/ihr Internet-Angebot: medikamio.com/ This website is certified by Health On the Net Foundation. Click to verify.

    Search our database for drugs, sorted from A-Z with their effects and ingredients.


    All substances with their common uses, chemical components and medical products which contain them.


    Causes, symptoms and treatment for the most common diseases and injuries.

    The contents shown do not replace the original package insert of the medicinal product, especially with regard to dosage and effect of the individual products. We cannot assume any liability for the correctness of the data, as the data was partly converted automatically. A doctor should always be consulted for diagnoses and other health questions. Further information on this topic can be found here.